Mr. Speaker, the government convened a panel to revise Canada's guidelines on opioid prescription. This is an important step to address the overdose crisis.
However, now we learn that one of the members of that panel was a paid adviser for pharmaceutical companies, including Purdue, a major opioid producer.
Given the record of misrepresentation by the drug industry that fed this crisis, how did the government allow an individual with a clear conflict of interest to help draft new prescription guidelines?